[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][N][Branch1][Ring2][C][Ring1][Ring2][C][=C][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][N][C][C@H1][N][Branch2][Ring1][#Branch1][C@H1][Branch1][Branch1][C][Ring1][=Branch1][=O][C][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][F][C][=Branch1][C][=O][C][N][Branch2][Ring1][Ring1][N][Ring2][Ring1][Ring1][C][=Branch1][C][=O][N][C][C][=C][C][=C][C][=C][Ring1][=Branch1][C][C][=C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors."}]